Grand Pharmaceutical Group (512.HK) Stock Price

Grand Pharmaceutical Group Price

🇭🇰HKEX·CLOSED
7.22HKD
Market closed
Today +/-
Today %

Grand Pharmaceutical Group (512.HK) Stock | ISIN BMG210A71016 | WKN A0Q8LD. The current Grand Pharmaceutical Group stock price is 7.22 HKD (2026). Revenue is 13.55 B HKD. Net income is 2.23 B HKD. The P/E ratio is 11.35. Market capitalization is 25.28 B HKD. Grand Pharmaceutical Group operates in the Health sector.

Over the last 19 years Grand Pharmaceutical Group grew revenue by 34.8% annually, reaching 12.28 B HKD. Earnings per share have grown at 19.2% per year over the last 16 years. For Grand Pharmaceutical Group, the net margin of 10.1% is down versus 27.9% a few years ago. At today's price the dividend yield works out to roughly 3.6%. The payout ratio is around 18% of earnings. The dividend has grown at 20.2% per year over the past 6 years.

Grand Pharmaceutical Group stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Grand Pharmaceutical Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Grand Pharmaceutical Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Grand Pharmaceutical Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Grand Pharmaceutical Group Stock Price History
DateGrand Pharmaceutical Group Price
Access this data via the Eulerpool API
Get Free API Key

Grand Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
42.4 M HKD
-6.8 M HKD
-10.7 M HKD
Jan 1, 2007
49 M HKD
-45.5 M HKD
-52 M HKD
Jan 1, 2008
269.9 M HKD
-2.1 M HKD
-24.2 M HKD
Jan 1, 2009
545.4 M HKD
52.8 M HKD
28.3 M HKD
Jan 1, 2010
1.05 B HKD
179.9 M HKD
98 M HKD
Jan 1, 2011
1.65 B HKD
116.2 M HKD
54.2 M HKD
Jan 1, 2012
2.06 B HKD
147.3 M HKD
67.3 M HKD
Jan 1, 2013
2.66 B HKD
188.8 M HKD
99.7 M HKD
Jan 1, 2014
3.12 B HKD
298.7 M HKD
175.21 M HKD
Jan 1, 2015
3.25 B HKD
354.39 M HKD
180.91 M HKD
Jan 1, 2016
3.7 B HKD
457.04 M HKD
269.14 M HKD
Jan 1, 2017
4.77 B HKD
692.94 M HKD
460.81 M HKD
Jan 1, 2018
5.96 B HKD
961.09 M HKD
712.67 M HKD
Jan 1, 2019
6.59 B HKD
1.34 B HKD
1.15 B HKD
Jan 1, 2020
6.35 B HKD
1.78 B HKD
1.79 B HKD

Grand Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 17, 2026, 8:58 PM
 
REVENUE (B HKD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B HKD)
NET INCOME (B HKD)
NET INCOME GROWTH (%)
DIV. (HKD)
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
2023202420252026e2027e2028e2029e2030e
10.5311.6412.2813.5515.6913.6214.0714.2
10.1110.595.4910.3315.79-13.223.340.92
61.9657.8755.250.0343.2149.7948.1847.74
6.526.746.786.786.786.786.786.78
1.882.471.242.232.62---
-9.5731.28-49.7679.6817.46–––
0.140.260.260.170.13---
27.2785.71–-34.62-23.53–––
3.513.53.53.53.53.53.53.5
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Grand Pharmaceutical Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Grand Pharmaceutical Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Grand Pharmaceutical Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Grand Pharmaceutical Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Grand Pharmaceutical Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Grand Pharmaceutical Group stock margins

The Grand Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Grand Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Grand Pharmaceutical Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
44.81 %
-16.04 %
-25.24 %
Jan 1, 2007
46.33 %
-92.86 %
-106.12 %
Jan 1, 2008
40.64 %
-0.78 %
-8.97 %
Jan 1, 2009
45.86 %
9.68 %
5.19 %
Jan 1, 2010
35.53 %
17.06 %
9.29 %
Jan 1, 2011
31.26 %
7.05 %
3.29 %
Jan 1, 2012
31.33 %
7.15 %
3.27 %
Jan 1, 2013
33.35 %
7.1 %
3.75 %
Jan 1, 2014
38.23 %
9.57 %
5.61 %
Jan 1, 2015
41.61 %
10.92 %
5.57 %
Jan 1, 2016
46.87 %
12.37 %
7.28 %
Jan 1, 2017
51.97 %
14.52 %
9.66 %
Jan 1, 2018
53.06 %
16.13 %
11.96 %
Jan 1, 2019
61.32 %
20.33 %
17.46 %
Jan 1, 2020
63.52 %
28.07 %
28.22 %

Grand Pharmaceutical Group Stock Revenue, EBIT, Earnings per Share

The Grand Pharmaceutical Group earnings per share therefore indicates how much revenue Grand Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0.04 HKD
-0.01 HKD
-0.01 HKD
Jan 1, 2007
0.04 HKD
-0.04 HKD
-0.05 HKD
Jan 1, 2008
0.24 HKD
-0 HKD
-0.02 HKD
Jan 1, 2009
0.41 HKD
0.04 HKD
0.02 HKD
Jan 1, 2010
0.7 HKD
0.12 HKD
0.06 HKD
Jan 1, 2011
0.85 HKD
0.06 HKD
0.03 HKD
Jan 1, 2012
1.05 HKD
0.08 HKD
0.03 HKD
Jan 1, 2013
1.35 HKD
0.1 HKD
0.05 HKD
Jan 1, 2014
1.54 HKD
0.15 HKD
0.09 HKD
Jan 1, 2015
1.46 HKD
0.16 HKD
0.08 HKD
Jan 1, 2016
1.59 HKD
0.2 HKD
0.12 HKD
Jan 1, 2017
1.91 HKD
0.28 HKD
0.18 HKD
Jan 1, 2018
2.13 HKD
0.34 HKD
0.26 HKD
Jan 1, 2019
1.95 HKD
0.4 HKD
0.34 HKD
Jan 1, 2020
1.84 HKD
0.52 HKD
0.52 HKD

Grand Pharmaceutical Group business model & stock analysis

China Grand Pharmaceutical and Healthcare Holdings Ltd is an innovative company in the healthcare and pharmaceutical industry in China. The company was founded in 1997 and is headquartered in Wuhan, Hubei Province. China Grand Pharma specializes in developing, manufacturing, and distributing high-quality medications, medical devices, and services. The company has multiple subsidiaries involved in various areas of the healthcare and pharmaceutical industry. China Grand Pharma’s main business areas include the production and sale of synthetic drugs, traditional Chinese medicines, biopharmaceuticals, veterinary medicine, and medical devices and equipment. The company has a high level of technological expertise in synthetic drug development and has a team of experienced scientists and researchers. China Grand Pharma has continuously invested in research and development to develop innovative and effective medications that meet the needs of patients in China and worldwide. The traditional Chinese medicine segment is another important area of China Grand Pharma’s business. The company holds a leading position in the market and offers a wide range of products made from natural plant extracts and traditional Chinese medicines. Biopharmaceuticals, based on innovative technologies such as recombinant DNA technology or stem cell research, are another important focus of China Grand Pharma. The company is able to develop and manufacture high-quality biopharmaceuticals that can be used for the prevention and treatment of serious diseases. China Grand Pharma is also a major player in the veterinary medicine market and offers a wide range of products for the health of livestock and pets. The company has a high level of technological expertise and has an extensive portfolio of products for the diagnosis, prevention, and treatment of animal diseases. The company also offers a wide range of medical devices and equipment for healthcare in hospitals and clinics. China Grand Pharma provides a variety of products, from diagnostic instruments to surgical tools. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd is one of the leading companies in the healthcare and pharmaceutical industry in China. The company has a comprehensive range of products and is able to provide high-quality products and services for a variety of applications and needs. China Grand Pharma is highly committed to researching and developing medications and technologies that can improve healthcare in China and enhance the lives of patients worldwide. The company has a strong presence in the Chinese market and has a well-established distribution infrastructure that allows it to distribute its products and services in China and beyond.

Grand Pharmaceutical Group SWOT Analysis

Strengths

China Grand Pharmaceutical and Healthcare Holdings Ltd holds a strong position in the pharmaceutical and healthcare industry in China. With its extensive product portfolio and well-established distribution network, the company has gained a significant market share.

The company heavily invests in research and development, which allows it to continuously innovate and develop new drugs and healthcare solutions. This helps China Grand Pharmaceutical and Healthcare Holdings Ltd stay ahead of its competitors and offer cutting-edge products.

The company offers a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and healthcare devices. This diversification in product offerings enables China Grand Pharmaceutical and Healthcare Holdings Ltd to cater to various customer needs and capture a larger market share.

Weaknesses

China Grand Pharmaceutical and Healthcare Holdings Ltd heavily relies on the domestic Chinese market for its revenue. This concentration exposes the company to risks associated with changes in government regulations, market fluctuations, and economic conditions within China.

The company has a relatively limited international presence compared to some of its global competitors. This restricts its access to overseas markets and potential growth opportunities beyond China.

While China Grand Pharmaceutical and Healthcare Holdings Ltd is well-known within the Chinese market, it still faces challenges in achieving strong brand recognition on a global scale. Building a reputable brand presence internationally may require additional investments and marketing efforts.

Opportunities

China's healthcare market is experiencing rapid growth due to an aging population, increasing disposable income, and government initiatives to enhance healthcare infrastructure. China Grand Pharmaceutical and Healthcare Holdings Ltd can capitalize on this favorable market environment to expand its business and increase sales.

The company has the potential to expand its operations beyond China and tap into the global pharmaceutical and healthcare markets. Strategic partnerships, acquisitions, and investments in research collaborations could help China Grand Pharmaceutical and Healthcare Holdings Ltd establish a stronger international presence.

Advancements in technology, such as digital health solutions, can provide opportunities for China Grand Pharmaceutical and Healthcare Holdings Ltd to develop innovative products and services that cater to the evolving needs of healthcare consumers.

Threats

The pharmaceutical and healthcare industry is highly competitive, both domestically and internationally. China Grand Pharmaceutical and Healthcare Holdings Ltd faces competition from both established players and emerging companies, which can impact its market share and profitability.

Government regulations and policies relating to pharmaceuticals and healthcare can change frequently, posing risks and uncertainties for China Grand Pharmaceutical and Healthcare Holdings Ltd. Compliance with evolving regulations and potential policy shifts can impact the company's operations and financial performance.

The healthcare industry is subject to pricing pressure, driven by factors such as government cost containment efforts, increasing generic competition, and negotiations with healthcare payers. China Grand Pharmaceutical and Healthcare Holdings Ltd must carefully manage pricing strategies to maintain profitability in this challenging market environment.

Grand Pharmaceutical Group Eulerpool Fair Value

Grand Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

Grand Pharmaceutical Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Grand Pharmaceutical Group shares outstanding

The number of shares was Grand Pharmaceutical Group in 2025 — This indicates how many shares 3.502 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
1.12 B base_Shares
Jan 1, 2007
1.12 B base_Shares
Jan 1, 2008
1.12 B base_Shares
Jan 1, 2009
1.32 B base_Shares
Jan 1, 2010
1.51 B base_Shares
Jan 1, 2011
1.93 B base_Shares
Jan 1, 2012
1.96 B base_Shares
Jan 1, 2013
1.97 B base_Shares
Jan 1, 2014
2.02 B base_Shares
Jan 1, 2015
2.22 B base_Shares
Jan 1, 2016
2.32 B base_Shares
Jan 1, 2017
2.5 B base_Shares
Jan 1, 2018
2.79 B base_Shares
Jan 1, 2019
3.37 B base_Shares
Jan 1, 2020
3.45 B base_Shares

Grand Pharmaceutical Group Dividend History

9 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.17HKDYTD—1×
Jun 12, 20260.17HKD↓ 35.0%1/1
20250.26HKD 0.0%1×
Apr 14, 20250.26HKD 0.0%1/1
20240.26HKD↑ 85.7%1×
20230.14HKD↑ 27.3%1×
20220.11HKD 0.0%1×
20210.11HKD↑ 14.6%1×
20200.1HKD↑ 11.6%1×
20190.09HKD↑ 32.3%1×
19960.07HKD—2×

Grand Pharmaceutical Group dividend history and estimates

In 2025, Grand Pharmaceutical Group paid a dividend amounting to 0.26 HKD. Dividend means that Grand Pharmaceutical Group distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.09 HKD
0.09 HKD
Jan 1, 2020
0.1 HKD
0 HKD
Jan 1, 2021
0.11 HKD
0 HKD
Jan 1, 2022
0.11 HKD
0 HKD
Jan 1, 2023
0.14 HKD
0 HKD
Jan 1, 2024
0.26 HKD
0 HKD
Jan 1, 2025
0.26 HKD
0 HKD
Jan 1, 2026
0.17 HKD
0 HKD
Invalid Date
0 HKD
0.13 HKD

Grand Pharmaceutical Group dividend payout ratio

In 2025, Grand Pharmaceutical Group had a payout ratio of 18.05%. The payout ratio indicates the percentage of the company's profits that Grand Pharmaceutical Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
17.81 %
Jan 1, 2007
17.81 %
Jan 1, 2008
17.81 %
Jan 1, 2009
17.81 %
Jan 1, 2010
17.81 %
Jan 1, 2011
17.81 %
Jan 1, 2012
17.81 %
Jan 1, 2013
17.81 %
Jan 1, 2014
17.81 %
Jan 1, 2015
17.81 %
Jan 1, 2016
17.81 %
Jan 1, 2017
17.81 %
Jan 1, 2018
17.81 %
Jan 1, 2019
24.99 %
Jan 1, 2020
18.45 %
Price targets and forecasts for Grand Pharmaceutical Group are not yet available.

Grand Pharmaceutical Group shareholder structure

% Name
54.14469%
Outwit Investments Ltd
Outwit Investments Ltd
8.7412%
CDH Investments
CDH Investments
8.16832%
Shanghai China Grand Asset Finance Investment Management Co Ltd
Shanghai China Grand Asset Finance Investment Management Co Ltd
2.49314%
GL China Long Equity Opportunities Fund SPV, L.P.
GL China Long Equity Opportunities Fund SPV, L.P.
2.48411%
GL Trade Investment Ltd.
GL Trade Investment Ltd.
1.18567%
Chau (Tung)
Chau (Tung)
0.98964%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.87476%
GF Fund Management Co., Ltd.
GF Fund Management Co., Ltd.
0.66544%
Ping An Fund Management Company Limited
Ping An Fund Management Company Limited
0.65222%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Grand Pharmaceutical Group Executives and Management Board

WT

Dr. Weikun Tang

(37)

Executive Chairman of the Board; President of Grand Pharma, China · since 2021

Compensation1.1 M HKD
TS

Ms. Tosi Wan So

(59)

Independent Non-Executive Director

Compensation180,000 HKD
YH

Mr. Yebi Hu

(60)

Independent Non-Executive Director

Compensation100,000 HKD
GP

Dr. Geng Pei

(62)

Independent Non-Executive Director

Compensation60,000 HKD
XS

Mr. Xiaofeng Shi

(55)

Chairman of the Board of Grand Pharma, China

Grand Pharmaceutical Group Supply Chain

Frequently asked questions about Grand Pharmaceutical Group

The business model of China Grand Pharmaceutical and Healthcare Holdings Ltd. revolves around its diverse healthcare portfolio. As a leading pharmaceutical company based in China, it engages in the research, development, production, and distribution of a wide range of pharmaceutical products and medical devices. The company's core focus lies in the fields of innovative drug discovery, modernized traditional Chinese medicine, and the provision of high-quality medical services. With a dedication to improving healthcare outcomes, China Grand Pharmaceutical and Healthcare Holdings Ltd. aims to meet the evolving needs of patients and healthcare professionals, while contributing to the advancement of the healthcare industry.

All fundamentals and in-depth analysis of Grand Pharmaceutical Group

Our stock analysis for Grand Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grand Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Revenue→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Net Income→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group P/E→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group P/S→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group EBIT→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Dividend→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Directors Dealings→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Stocks→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Market capitalization→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Debt→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Liabilities→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Equity→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group AAQS→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group Employees→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group ROE→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group ROA→
Grand Pharmaceutical Group Stock
Grand Pharmaceutical Group ROCE→